ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0302

TNFAIP3 Loss-of-function and Missense Mutations Demonstrate Clinically Diverse Presentations: A Multi-center Cohort Experience

Elizabeth Kairis1, Manuel Carpio Tumba1, Urekha Karri1, Magdalena Harasimowicz1, Megan Cooper2, Lance Peterson2, Priscilla Campbell-Stokes3, Juan Carlos Aldave-Becerra4, Ana Beatriz Muñoz-Urribarri4 and Daniella Schwartz1, 1University of Pittsburgh, Pittsburgh, PA, 2Washington University School of Medicine, St. Louis, MO, 3Child Health Service, Hutt Hospital, National Pediatric Rheumatologic Service, Te Whatu Ora, New Zealand, 4Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Autoinflammatory diseases, genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: A20 is a critical anti-inflammatory protein encoded by the TNFAIP3 (tumor necrosis factor alpha-induced protein 3) gene. A20 negatively regulates multiple anti-inflammatory pathways including TNF-NFκB signaling, inflammasome activation, and interferon (IFN) signaling. Inactivating mutations in TNFAIP3 cause the monogenic disease A20 haploinsufficiency (HA20). HA20 is classically considered as a form of atypical Behcet’s disease. However, recent data suggest that HA20 causes diverse clinical signs and symptoms of autoinflammation, autoimmunity, lymphoproliferation, and humoral immunodeficiency. These diverse clinical presentations have only been characterized through meta-analyses of reported cases, leading to potential ascertainment bias. We therefore aimed to better characterize the clinical presentations of patients with truncating mutations in TNFAIP3 who were systematically analyzed through the University of Pittsburgh-NIH HA20 cohort (n = 50).

Methods: Patients and families with TNFAIP3 truncating or missense mutations were identified through patient referral. Patients underwent Invitae Primary Immunodeficiency (PID) panel sequencing at >50x coverage. Families underwent comprehensive evaluation to determine clinical course and inheritance patterns.

Results: 41 pLOF patients (age range 3-74, 56% male) and 9 missense patients (age range 3-87, 56% male) were included in this cohort.

pLOF (%)

Missense (%)

Autoinflammation alone

17.0

66.7

Autoimmunity alone

7.3

11.1

Autoinflammation and autoimmunity

70.7

22.2

Immunodeficiency

29.3

33.3

  

pLOF (%)

Missense (%)

Oral ulceration

85

55.6

Lymphopenia

68

0

Arthritis/arthralgia

63

77.8

Recurrent fever

51

55.6

Elevated serum ALT/AST

49

0

Anemia

49

22.2

Conclusion: HA20 is classically characterized as atypical Bechet’s disease, yet these patients experience widely diverse clinical presentations. This diversity is observed when comparing those with pLOF and missense mutations as well as within these respective patient populations. In addition, HA20 patients are at increased risk for life-threatening complications such as autoimmune hepatitis and vasculitis. Ascertainment bias can limit diagnosis if genetic testing is only performed on subjects with atypical Behcet’s disease, leading to missed opportunities for targeted therapy. Future studies are needed to better characterize the molecular drivers of HA20 phenotypes in patients with pLOF and missense TNFAIP3 variants to guide appropriate screenings and treatment for these patient populations.


Disclosures: E. Kairis: None; M. Carpio Tumba: None; U. Karri: None; M. Harasimowicz: None; M. Cooper: Pharming, 2, sumitomo, 2; L. Peterson: None; P. Campbell-Stokes: None; J. Aldave-Becerra: None; A. Muñoz-Urribarri: None; D. Schwartz: Eli Lilly, 5, Sobi, 2.

To cite this abstract in AMA style:

Kairis E, Carpio Tumba M, Karri U, Harasimowicz M, Cooper M, Peterson L, Campbell-Stokes P, Aldave-Becerra J, Muñoz-Urribarri A, Schwartz D. TNFAIP3 Loss-of-function and Missense Mutations Demonstrate Clinically Diverse Presentations: A Multi-center Cohort Experience [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/tnfaip3-loss-of-function-and-missense-mutations-demonstrate-clinically-diverse-presentations-a-multi-center-cohort-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tnfaip3-loss-of-function-and-missense-mutations-demonstrate-clinically-diverse-presentations-a-multi-center-cohort-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology